Developer docs
API playgroundTry for free, no card

Search company profiles

L-CMD Research Foundation

Full company profile

uuid00v1pkb

Namestring
L-CMD Research Foundation
Legal namestring
L-CMD Research Foundation
Company typeenum
Private
Founded yearint
2020
Descriptiontext

L-CMD Research Foundation is a 501(c)(3) nonprofit organization founded in February 2020 by Hannah Lowe and Mark Corman in Houston, Texas, after their son Austin was diagnosed with LMNA-related congenital muscular dystrophy (L-CMD) at five months old. The foundation is dedicated to funding and coordinating scientific research aimed at developing treatments and ultimately a cure for L-CMD, a rare and fatal form of muscular dystrophy caused by randomly occurring DNA mutations in the LMNA gene that prevents affected children from achieving walking and leads to dramatically shortened lifespans due to progressive muscle weakness, particularly of the heart. At least 200 children worldwide are affected, and no treatments or cures currently exist.

The foundation's research focus centers on gene therapy approaches, including novel gene editing methods and muscle-targeted formulations. Its primary research partnership is with Entos Pharmaceuticals, announced April 2026, to co-develop a potentially curative therapy leveraging Entos's Fusogenix PLV non-viral drug delivery platform designed to enable redosable gene therapies. The foundation also participates in the CMDIR patient registry to support clinical trial readiness and structured patient data.

The organization operates a community-led go-to-market model, raising funds through grassroots campaigns (notably the '2 Before 2!' initiative), recurring fundraising events (silent auctions, cocktail parties, fitness classes, wine tastings, art auctions, neighborhood sales, and birthday fundraisers), and a diversified donation infrastructure that includes online portals (Givebutter, GoFundMe), direct mail, appreciated stock transfers via TD Ameritrade, cryptocurrency, IRA qualified charitable distributions, donor-advised funds, and corporate matching programs. Earned media coverage spans Good Morning America, ABC News, the Houston Chronicle, and podcasts including Once Upon A Gene. Cumulative funds raised exceed $2.5 million since founding. The foundation does not sell products or services and is governed by a Board of Directors.

Short descriptiontext

L-CMD Research Foundation is a 501(c)(3) nonprofit founded in 2020 that funds and advances gene therapy research for LMNA-related congenital muscular dystrophy, a fatal pediatric disease affecting at least 200 children worldwide, and partners with Entos Pharmaceuticals on curative treatment development.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
rare disease research, muscular dystrophy research, medical research funding, nonprofit foundation, gene therapy funding
Industry2 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Health Services8000
Product category
Nonprofit Medical Research Foundation
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Charitable Donations
TypeOthers
Description

Tax-deductible donations from individual donors supporting L-CMD research. Accepts donations via website, social media fundraisers, and direct contributions.

lcmdresearch.org
2Fundraising Events
TypeOthers
Description

Revenue from organized events including silent auctions, cocktail parties, fitness classes, art auctions, wine tastings, lemonade stands, and birthday fundraisers. Events are held both virtually and in-person across various cities.

lcmdresearch.org
3Stock and Crypto Donations
TypeOthers
Description

Accepts donations via appreciated stock, cryptocurrency, and donor advised funds (DAF). Stock donations can be made through TD Ameritrade with account details provided on the foundation's website.

lcmdresearch.org
4IRA and DAF Donations
TypeOthers
Description

Accepts qualified charitable distributions from IRAs and donations through donor advised funds for tax-advantaged giving.

lcmdresearch.org
5Corporate Matching and Sponsorships
TypeOthers
Description

Corporate donors and sponsors provide support. The foundation actively advocates for workplace charitable giving program inclusion.

lcmdresearch.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Marketing or Sales, Operations, Others
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

L-CMD Research Foundation is a 501(c)(3) nonprofit that funds and coordinates scientific research into treatments and a cure for LMNA-related congenital muscular dystrophy (L-CMD). It runs community-driven fundraising campaigns, maintains a patient registry via CMDIR, and partners with biopharmaceutical researchers (notably Entos Pharmaceuticals) to advance gene therapy development using the Fusogenix PLV non-viral delivery platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • At least 200 children worldwide affected by L-CMD have no treatments or cures, representing the unmet medical need the foundation addresses.
Product overview1 text field

L-CMD Research Foundation is a 501(c)(3) nonprofit organization (EIN: 85-2640499) dedicated to funding scientific research for treatments and a cure for LMNA-related congenital muscular dystrophy (L-CMD), a fatal genetic condition affecting children. The foundation operates as a fundraising and research advocacy organization rather than a technology product company. Its core activities include running fundraising campaigns (such as the '2 Before 2!' initiative), facilitating research collaborations with scientific partners (including Entos Pharmaceuticals for gene therapy development), and providing resources and community support for affected families. The foundation does not offer software products, platforms, or technology services.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-20
Description

Collaboration to develop a potentially curative genetic therapy for LMNA-related congenital muscular dystrophy (L-CMD). The partnership combines Entos's Fusogenix PLV non-viral drug delivery platform with novel gene editing approaches and muscle-targeted formulations to create redosable gene therapies. The organizations aim to leverage emerging FDA regulatory pathways to accelerate development of treatments for this rare pediatric condition affecting at least 200 children worldwide.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Parent-founded nonprofit focused on Duchenne muscular dystrophy — closely mirrors the L-CMD Research Foundation's parent-led, single-disease, gene-therapy-oriented operating model and is a useful scale benchmark.

TypeDirect peer
Description

Disease-specific nonprofit foundation funding Duchenne muscular dystrophy research and providing patient/family support — directly analogous operating model to L-CMD Research Foundation, with a more mature scale demonstrating the trajectory of such organizations.

TypeOthers
Description

Core technology partner developing the Fusogenix PLV non-viral delivery platform used in the L-CMD collaboration. Included as a peer because the foundation's therapeutic trajectory is materially tied to Entos's platform execution.

TypeEmerging player
Description

Clinical-stage gene therapy company developing treatments for Duchenne and other neuromuscular diseases — comparable as a muscular-dystrophy-focused gene therapy developer with which the foundation's research efforts could eventually align.

TypeDirect peer
Description

Disease-specific nonprofit funding Duchenne research, with strong ties to gene therapy developers and patient registries — operates a similar model to L-CMD Research Foundation but has built a more developed venture philanthropy arm.

6A Foundation Building Strength
TypeDirect peer
Description

Parent-founded nonprofit dedicated to collagen VI congenital muscular dystrophy (a related CMD subtype) — directly comparable disease-area, structure, and gene-therapy orientation, and a relevant peer for benchmarking fundraising maturity.

TypeBroad incumbent
Description

The largest US muscular dystrophy advocacy and research-funding organization, covering many subtypes including CMD. Comparable as a fundraising/funding-orchestration entity, but operates at much larger scale and broader scope.

TypeBroad incumbent
Description

Commercial-stage gene therapy company with approved and pipeline programs in Duchenne and limb-girdle muscular dystrophies. Relevant as the type of strategic acquirer the foundation's research could eventually feed into.

TypeDirect peer
Description

Spinal muscular atrophy-focused nonprofit that funded the research path to recently approved SMA gene-targeting therapies — the gold-standard comparable for a rare pediatric neuromuscular disease foundation that has translated funding into approved treatments.

10Coalition to Cure Calpain 3
TypeDirect peer
Description

Small patient-founded nonprofit funding calpainopathy/LGMD2A research — highly comparable in scale, mission (single rare muscular dystrophy subtype), and funding-driven operating model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

L-CMD Research Foundation

Nonprofit Medical Research Foundationlcmdresearch.org

L-CMD Research Foundation is a 501(c)(3) nonprofit founded in 2020 that funds and advances gene therapy research for LMNA-related congenital muscular dystrophy, a fatal pediatric disease affecting at least 200 children worldwide, and partners with Entos Pharmaceuticals on curative treatment development.

What L-CMD Research Foundation does

L-CMD Research Foundation is a 501(c)(3) nonprofit organization founded in February 2020 by Hannah Lowe and Mark Corman in Houston, Texas, after their son Austin was diagnosed with LMNA-related congenital muscular dystrophy (L-CMD) at five months old. The foundation is dedicated to funding and coordinating scientific research aimed at developing treatments and ultimately a cure for L-CMD, a rare and fatal form of muscular dystrophy caused by randomly occurring DNA mutations in the LMNA gene that prevents affected children from achieving walking and leads to dramatically shortened lifespans due to progressive muscle weakness, particularly of the heart. At least 200 children worldwide are affected, and no treatments or cures currently exist.

The foundation's research focus centers on gene therapy approaches, including novel gene editing methods and muscle-targeted formulations. Its primary research partnership is with Entos Pharmaceuticals, announced April 2026, to co-develop a potentially curative therapy leveraging Entos's Fusogenix PLV non-viral drug delivery platform designed to enable redosable gene therapies. The foundation also participates in the CMDIR patient registry to support clinical trial readiness and structured patient data.

The organization operates a community-led go-to-market model, raising funds through grassroots campaigns (notably the '2 Before 2!' initiative), recurring fundraising events (silent auctions, cocktail parties, fitness classes, wine tastings, art auctions, neighborhood sales, and birthday fundraisers), and a diversified donation infrastructure that includes online portals (Givebutter, GoFundMe), direct mail, appreciated stock transfers via TD Ameritrade, cryptocurrency, IRA qualified charitable distributions, donor-advised funds, and corporate matching programs. Earned media coverage spans Good Morning America, ABC News, the Houston Chronicle, and podcasts including Once Upon A Gene. Cumulative funds raised exceed $2.5 million since founding. The foundation does not sell products or services and is governed by a Board of Directors.

L-CMD Research Foundation firmographics

Firmographics
Name
L-CMD Research Foundation
Legal name
L-CMD Research Foundation
Website
https://lcmdresearch.org
Company type
Private
Founded year
2020
Operating status
Operating
Short description
L-CMD Research Foundation is a 501(c)(3) nonprofit founded in 2020 that funds and advances gene therapy research for LMNA-related congenital muscular dystrophy, a fatal pediatric disease affecting at least 200 children worldwide, and partners with Entos Pharmaceuticals on curative treatment development.
Ownership category
akta.pro rank

L-CMD Research Foundation industry classification

Industry
Product category
Nonprofit Medical Research Foundation
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Rare disease research
  • Muscular dystrophy research
  • Medical research funding
  • Nonprofit foundation
  • Gene therapy funding

Where L-CMD Research Foundation is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Markets served

L-CMD Research Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Charitable Donations: Tax-deductible donations from individual donors supporting L-CMD research. Accepts donations via website, social media fundraisers, and direct contributions.
  2. Fundraising Events: Revenue from organized events including silent auctions, cocktail parties, fitness classes, art auctions, wine tastings, lemonade stands, and birthday fundraisers. Events are held both virtually and in-person across various cities.
  3. Stock and Crypto Donations: Accepts donations via appreciated stock, cryptocurrency, and donor advised funds (DAF). Stock donations can be made through TD Ameritrade with account details provided on the foundation's website.
  4. IRA and DAF Donations: Accepts qualified charitable distributions from IRAs and donations through donor advised funds for tax-advantaged giving.
  5. Corporate Matching and Sponsorships: Corporate donors and sponsors provide support. The foundation actively advocates for workplace charitable giving program inclusion.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

L-CMD Research Foundation product offering

Product offering

Core offering

L-CMD Research Foundation is a 501(c)(3) nonprofit that funds and coordinates scientific research into treatments and a cure for LMNA-related congenital muscular dystrophy (L-CMD). It runs community-driven fundraising campaigns, maintains a patient registry via CMDIR, and partners with biopharmaceutical researchers (notably Entos Pharmaceuticals) to advance gene therapy development using the Fusogenix PLV non-viral delivery platform.

Product overview

L-CMD Research Foundation is a 501(c)(3) nonprofit organization (EIN: 85-2640499) dedicated to funding scientific research for treatments and a cure for LMNA-related congenital muscular dystrophy (L-CMD), a fatal genetic condition affecting children. The foundation operates as a fundraising and research advocacy organization rather than a technology product company. Its core activities include running fundraising campaigns (such as the '2 Before 2!' initiative), facilitating research collaborations with scientific partners (including Entos Pharmaceuticals for gene therapy development), and providing resources and community support for affected families. The foundation does not offer software products, platforms, or technology services.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • At least 200 children worldwide affected by L-CMD have no treatments or cures, representing the unmet medical need the foundation addresses.

Companies that use L-CMD Research Foundation

Customer profile

Segments1 record

Ideal customer profiles2 records

L-CMD Research Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

L-CMD Research Foundation partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Entos PharmaceuticalscoreStrategic or Co-development Partner · 20 April 2026Collaboration to develop a potentially curative genetic therapy for LMNA-related congenital muscular dystrophy (L-CMD). The partnership combines Entos's Fusogenix PLV non-viral drug delivery platform with novel gene editing approaches and muscle-targeted formulations to create redosable gene therapies. The organizations aim to leverage emerging FDA regulatory pathways to accelerate development of treatments for this rare pediatric condition affecting at least 200 children worldwide.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

L-CMD Research Foundation competitors and assessment

Company assessment

Direct peers

  • Charley's Fund: Parent-founded nonprofit focused on Duchenne muscular dystrophy — closely mirrors the L-CMD Research Foundation's parent-led, single-disease, gene-therapy-oriented operating model and is a useful scale benchmark.
  • Parent Project Muscular Dystrophy: Disease-specific nonprofit foundation funding Duchenne muscular dystrophy research and providing patient/family support — directly analogous operating model to L-CMD Research Foundation, with a more mature scale demonstrating the trajectory of such organizations.
  • CureDuchenne: Disease-specific nonprofit funding Duchenne research, with strong ties to gene therapy developers and patient registries — operates a similar model to L-CMD Research Foundation but has built a more developed venture philanthropy arm.
  • A Foundation Building Strength: Parent-founded nonprofit dedicated to collagen VI congenital muscular dystrophy (a related CMD subtype) — directly comparable disease-area, structure, and gene-therapy orientation, and a relevant peer for benchmarking fundraising maturity.
  • Cure SMA: Spinal muscular atrophy-focused nonprofit that funded the research path to recently approved SMA gene-targeting therapies — the gold-standard comparable for a rare pediatric neuromuscular disease foundation that has translated funding into approved treatments.
  • Coalition to Cure Calpain 3: Small patient-founded nonprofit funding calpainopathy/LGMD2A research — highly comparable in scale, mission (single rare muscular dystrophy subtype), and funding-driven operating model.

Others

  • Entos Pharmaceuticals: Core technology partner developing the Fusogenix PLV non-viral delivery platform used in the L-CMD collaboration. Included as a peer because the foundation's therapeutic trajectory is materially tied to Entos's platform execution.

Emerging players

  • SOLID Biosciences: Clinical-stage gene therapy company developing treatments for Duchenne and other neuromuscular diseases — comparable as a muscular-dystrophy-focused gene therapy developer with which the foundation's research efforts could eventually align.

Broad incumbents

  • Muscular Dystrophy Association (MDA): The largest US muscular dystrophy advocacy and research-funding organization, covering many subtypes including CMD. Comparable as a fundraising/funding-orchestration entity, but operates at much larger scale and broader scope.
  • Sarepta Therapeutics: Commercial-stage gene therapy company with approved and pipeline programs in Duchenne and limb-girdle muscular dystrophies. Relevant as the type of strategic acquirer the foundation's research could eventually feed into.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

L-CMD Research Foundation social profiles

Digital presence

L-CMD Research Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

L-CMD Research Foundation leadership team

Management profile

Number of profiles

Profiles1 record

L-CMD Research Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

L-CMD Research Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about L-CMD Research Foundation

What does L-CMD Research Foundation do?

L-CMD Research Foundation is a 501(c)(3) nonprofit that funds and coordinates scientific research into treatments and a cure for LMNA-related congenital muscular dystrophy (L-CMD). It runs community-driven fundraising campaigns, maintains a patient registry via CMDIR, and partners with biopharmaceutical researchers (notably Entos Pharmaceuticals) to advance gene therapy development using the Fusogenix PLV non-viral delivery platform.

Is L-CMD Research Foundation a public or private company?

L-CMD Research Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was L-CMD Research Foundation founded?

L-CMD Research Foundation was founded in 2020.

Where is L-CMD Research Foundation based?

L-CMD Research Foundation is headquartered in Houston, United States, in the North America region.

How does L-CMD Research Foundation make money?

Five revenue lines are on record. Charitable Donations are the primary driver. The others are fundraising Events, stock and Crypto Donations, IRA and DAF Donations and corporate Matching and Sponsorships.

Who are L-CMD Research Foundation's main competitors?

Direct peers on record are Charley's Fund, Parent Project Muscular Dystrophy, CureDuchenne, A Foundation Building Strength, Cure SMA and Coalition to Cure Calpain 3. Entos Pharmaceuticals is listed as an others. SOLID Biosciences is listed as an emerging player. Broad incumbents are Muscular Dystrophy Association (MDA) and Sarepta Therapeutics.

Does L-CMD Research Foundation have an API?

No public API is recorded for L-CMD Research Foundation.

What industry is L-CMD Research Foundation in?

L-CMD Research Foundation's product category is Nonprofit Medical Research Foundation. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 541714 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldEntos and L-CMD Research Foundation collaborateEntos Pharmaceuticals Inc. has established a collaboration with the L-CMD Research Foundation to develop a curative therapy for LMNA-related congenital muscular dystrophy (L-CMD). The partnership aims to address this rare neuromuscular disease through gene therapy.Financial PostEntos Pharmaceuticals and the L-CMD Research Foundation Collaborate to Develop Curative Therapy for LMNA-Related Congenital Muscular DystrophyEntos Pharmaceuticals has announced a collaboration with the L-CMD Research Foundation to develop a potentially curative genetic therapy for LMNA-related congenital muscular dystrophy, a fatal condition affecting at least 200 children worldwide with no existing treatments or cures. The partnership will combine Entos's Fusogenix PLV drug delivery platform with novel gene editing approaches to create redosable therapies targeting this currently untreatable disease. The companies aim to leverage emerging FDA regulatory pathways to accelerate development of treatments for this rare pediatric condition.Business Wire BlogEntos Pharmaceuticals and the L-CMD Research Foundation Collaborate to Develop Curative Therapy for LMNA-Related Congenital Muscular DystrophyEntos Pharmaceuticals and the L-CMD Research Foundation announced a collaboration to develop a curative gene therapy for LMNA-related congenital muscular dystrophy (L-CMD), a severe form of fatal muscular dystrophy affecting at least 200 children worldwide with no existing treatments or cures. The partnership leverages Entos' Fusogenix PLV non-viral delivery platform with novel gene editing approaches and muscle-targeted formulations to create potentially curative therapies. The organizations aim to utilize emerging FDA regulatory pathways to make these genetic medicines accessible to patients suffering from this currently untreatable condition.